Current Edition

enrollment

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of …

Continue Reading →
.

Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer

Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing cancer treatment drugs, announces today that its most advanced compound, GNS561, has received approval …

Continue Reading →